Current Neuropharmacology
Title:Meet the Editorial Board Member
Volume: 13 Issue: 1
Author(s): Ben A. Bahr
Affiliation:
Export Options
About this article
Cite this article as:
Bahr A. Ben, Meet the Editorial Board Member, Current Neuropharmacology 2015; 13 (1) . https://dx.doi.org/10.2174/1570159X1301150413144312
DOI https://dx.doi.org/10.2174/1570159X1301150413144312 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
17
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Applying Auto-Regressive Model’s Yule-Walker Approach to Amyotrophic Lateral Sclerosis (ALS) patients’ Data
Current Medical Imaging Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds
Medicinal Chemistry The Effect of Levosimendan on Two Distinct Rodent Models of Parkinson’s Disease
Current Alzheimer Research Vitamin D: Preventive and Therapeutic Potential in Parkinson’s disease
Current Drug Metabolism Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation
Current Alzheimer Research When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy
Current Pharmaceutical Design Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2
Current Protein & Peptide Science Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry Cyclin-Dependent Kinase Inhibitors: Cancer Killers to Neuronal Guardians
Current Medicinal Chemistry Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways
Current Signal Transduction Therapy Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update
Current Neuropharmacology The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research